Table 1.
Characteristics of the whole study population.
| Variables | Category | All Patients |
|---|---|---|
| Number | 336 | |
| Age (years) | median (range) | 71 (19 to 89) |
| Sex, n (%) | Female | 54 (16.1) |
| Male | 282 (83.9) | |
| ECOG PS, n (%) | 0 | 279 (83.0) |
| 1 | 49 (14.5) | |
| 2 | 8 (2.5) | |
| Body mass index (kg/m2) | median (range) | 23.1 (11.2 to 32.8) |
| Etiology, n (%) | Viral | 237 (71.0) |
| Non-Viral | 99 (29.0) | |
| Child–Pugh class, n (%) | A | 312 (92.9) |
| B | 24 (7.1) | |
| ALBI score | median (range) | −2.54 (−3.61 to −0.91) |
| ALBI grade, n (%) | 1 or 2a | 234 (69.6) |
| 2b or 3 | 102 (30.4) | |
| BCLC stage, n (%) | B | 125 (37.2) |
| C | 211 (62.8) | |
| Maximum intrahepatic tumor size, cm | median (range) | 2.8 (0 to 25) |
| Intrahepatic tumor number, n (%) | ≤4 | 156 (46.4) |
| ≥5 | 180 (53.6) | |
| Macrovascular invasion, n (%) | Absent | 251 (74.7) |
| Present | 85 (25.3) | |
| Extrahepatic metastasis, n (%) | Absent | 179 (53.3) |
| Present | 157 (46.7) | |
| AFP (ng/mL) | median (range) | 54 (0.9 to 1,057,992) |
| AFP ≥ 400 ng/mL, n (%) | Absent | 224 (66.7) |
| Present | 112 (33.3) | |
| The number of systemic therapy lines | 1 | 248 (73.8) |
| 2 | 50 (14.9) | |
| 3 | 24 (7.1) | |
| ≥4 | 14 (4.2) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; ALBI, albumin–bilirubin; BCLC, Barcelona Clinic Liver Cancer stage; AFP, alpha-fetoprotein.